NCT05161637View on ClinicalTrials.gov

Phase 2/3 Study of TLC590 for Postsurgical Pain Management

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Postsurgical Pain Management
Interventions
DRUG

TLC590

TLC590 490mg or 588mg

DRUG

Bupivacain

Bupivacaine 75mg

DRUG

Ropivacaine

Ropivacaine 150mg

DRUG

Normal saline

Normal saline 20mL or 24mL

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY

NCT05161637 - Phase 2/3 Study of TLC590 for Postsurgical Pain Management | Biotech Hunter | Biotech Hunter